Remeglurant

Remeglurant (INN; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu5 receptor.[1][2][3] It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.[3]

Remeglurant
Clinical data
Other namesMRZ-8456
ATC code
  • None
Identifiers
IUPAC name
  • (6-Bromopyrazolo[1,5-a]pyrimidin-2-yl)[(1R)-1-methyl-3,4-dihydro-2(1H)-isoquinolinyl]methanone
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC17H15BrN4O
Molar mass371.238 g·mol−1
3D model (JSmol)
SMILES
  • C[C@@H]1c2ccccc2CCN1C(=O)c3cc4ncc(cn4n3)Br
InChI
  • InChI=1S/C17H15BrN4O/c1-11-14-5-3-2-4-12(14)6-7-21(11)17(23)15-8-16-19-9-13(18)10-22(16)20-15/h2-5,8-11H,6-7H2,1H3/t11-/m1/s1
  • Key:TUYZYSNXXSTKQX-LLVKDONJSA-N

See also

References
  1. World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 109" (PDF). WHO Drug Information. World Health Organization. 27 (2).
  2. US 7985753, Danysz W, Dekundy A, Hechenberger M, Henrich M, Jatzke C, Nagel J, Parsons CG, Weil T, Fotins J, Gutcaits A, Kalvinsh I, Zemribo R, Kauss V, "Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators.", issued 4 August 2006, assigned to Merz Pharmaceuticals GmbH
  3. "Remeglurant". Adis Insight. Springer Nature Switzerland AG.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.